TY - JOUR AB - Altered glucose metabolism is an important characteristic of cancer cells, which is referred to as Warburg effect or aerobic glycolysis. Ewing sarcoma (EWS) is a highly malignant tumor that occurs in children and adolescents. However, the functions of aerobic glycolysis in EWS remain to be elucidated. The present study identified a transcription factor, E2F transcription factor 1 (E2F1), as a new regulator of cancer the aerobic glycolysis and progression in EWS. The present study showed that E2F1 modulated aerobic glycolysis in EWS cells by effecting glucose uptake, lactate production and ATP generation. Altered E2F1 expression increased or decreased cell viability and invasion in EWS. Mechanistically, the results demonstrated that E2F1 may promote the Warburg effect and cancer progression in EWS via upregulating enolase 2 expression. Generally, these findings indicated that E2F1 involvement in the progression of EWS and could serve as a clinical therapeutic target in EWS. AD - Department of Orthopedics, Wuhan Hanyang Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430050, P.R. China Department of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China Medical Examination Center, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China AU - Jiang,Xianyong AU - Chen,Zhen AU - Zhu,Junping AU - Han,Jun AU - You,Gaoliang AU - Li,Yonghong AU - Liu,Tiancheng AU - Ye,Heng DA - 2022/07/01 DO - 10.3892/mmr.2022.12753 IS - 1 JO - Mol Med Rep KW - E2F transcription factor 1 aerobic glycolysis cancer progression Ewing sarcoma PY - 2022 SN - 1791-2997 1791-3004 SP - 237 ST - E2F1 promotes Warburg effect and cancer progression via upregulating ENO2 expression in Ewing sarcoma T2 - Molecular Medicine Reports TI - E2F1 promotes Warburg effect and cancer progression via upregulating ENO2 expression in Ewing sarcoma UR - https://doi.org/10.3892/mmr.2022.12753 VL - 26 ER -